Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I did too, last week. The CEO has a ton of shares already and throws $50,000 of his own money in? If there is one thing I don't ignore it's insider buying. He could play it safe and exercise his .20 options after something major happens. I will say the daily volume is not encouraging but this stock is off just about everyone's radar.
Century that's a great post! Thank you for your contributions on this message board. Shares available to short is showing 1,100,000 right now.
Recruitment for the IMAGINE trail completed.
Melbourne - 27 November, 2012: Prana Biotechnology (NASDAQ:PRAN; ASX:PBT) today announced that it has completed recruitment in the IMAGINE trial, a 12 month Phase II trial testing PBT2, the Company's drug in development for Alzheimer's Disease.
The double-blind placebo controlled trial has enrolled 41 patients with prodromal or mild Alzheimer's Disease in Melbourne, Australia. One additional patient may be included in the trial, subject to final screening procedures this week. All trial participants are undergoing brain scans to measure PBT2's effect on amyloid deposits in the brain (using PiB-PET scanning) and effects on increasing brain activity (F-FDG PET). Cognition effects are being measured by the Neuropsychological Test Battery (NTB), a test that measures the type of cognitive problems experienced by prodromal and early Alzheimer's patients.
In an earlier 12 week Alzheimer's Disease trial, PBT2 significantly reduced the level of Abeta protein in the spinal fluid of treated patients as well as significantly improving their cognitive Executive Function1,2,3.
"We expect that the current 12 month IMAGINE trial will provide further evidence of PBT2's ability to have a positive effect in the brain and help Alzheimer's patients," said Prana's Executive Chairman, Mr Geoffrey Kempler.
The scientific data supporting the belief that PBT2 will bring meaningful clinical benefit to patients is extensive. PBT2 restores neuronal health by selectively binding and redistributing brain metals (copper, zinc) that have become imbalanced due to disease or the ageing process. Furthermore PBT2 is able to prevent Abeta protein induced toxicity and promote its disaggregation in the brain.
The trial has received funding from the Alzheimer's Drug Discovery Foundation (ADDF). Howard Fillit, MD, the ADDF's Executive Director commented that "PBT2 stands out as one of the few remaining orally available agents with clinical trial evidence of cognitive benefit for Alzheimer's patients. Success in this trial will demonstrate target engagement by PBT2 in the brains of people with Alzheimer's Disease, and accelerate the clinical development of PBT2 to patients".
Alzheimer's Disease and dementia affects over 26 million people worldwide. The cost to society has been reported as $600 billion per annum. Currently all available treatments are approved to provide some degree of symptomatic relief. None change the course of the disease and the eventual decline in patient's cognition and health. PBT2 has the potential to be an effective treatment for Alzheimer's Disease that is supported by an extensive body of scientific and clinical work.
Here is a link where you can register to listen in on the conference. You'll have to make a account first, really easy to do. Well worth it.
http://www.nyas.org/Events/Detail.aspx?cid=1c84a5bc-6abb-4a61-9ac1-6bf360b4c096
It's nice to see the stock behaving well during a down day. Seems less volatile than normal.
That's interesting Buzz, I'd like read it to get a better grasp of Tom's philosophy. I can't find a free one online, might have to bite the bullet on Amazon.
You can't go wrong with money invested in Intel. I bought a 1000 shares last year in the 19's and sold it in the spring above $28. I just bought some back a week ago. I can only shake my head when I hear about the dying PC market. The economy sucks and people are running laptops and desktops into the ground. I remember when we use to replace them just because they looked dated not because there was anything wrong with them. My laptop is 5 years old and runs like a champ.
Tablets might be offsetting sales currently, but they're more of a fad in my opinion. People want a real keyboard for many tasks. And keep in mind something like 5 billion people in the world still don't even have a computer. China an India's lower class are making considerably more money now and are buying computers in droves. Intel will pull through and pay a 4% dividend in the meantime. They did miss the smartphone boat but that scenery is always changing and when they have a product that stacks up I'm sure it will be adopted in one way or another.
That explains the missing volume. Thanks for clarifying that Walter. I agree it's very encouraging to see the CEO put his own money in.
Consider the reasons for the Otellini leaving, it may helpful to Lightwave’s cause. Intel may need to step up R&D and use more of their cash to do good acquisitions that will help their future pipeline of products and patents better.
Probably because ARNA shareholders were already expecting good insurance coverage while VVUS shareholders were aware they hardly get any.
I thought it was the EOD price that had to stay at or over $1? I'll have to check iTunes for that song, haha.
Avita initiates European ReCell trial in lower limb ulcers. November 20, 2012.
Avita Medical (ASX:AVH; OTCQX:AVMXY) has initiated a multicenter, randomized control study on the use of ReCell Spray-On Skin in the treatment of venous leg ulcers at up to five European centers in the UK, Germany, France and Denmark.
Up to 80 patients will be enrolled in the study. Study protocols have been submitted for approval by the relevant ethics review boards at each center. It is anticipated that enrolment in the study will begin during the first quarter of 2013.
In preliminary open-label studies, ReCell was used at four European centers to treat approximately 80 patients suffering from venous leg ulcers and diabetic foot ulcers. Results have been encouraging. Over 70% of patients showed complete healing of the wound within seven-to-12 weeks after a single treatment with ReCell.
With the current standard of care treatment, the company said it would be expected that about 43% of these wounds would have achieved closure during this period, indicating that ReCell appears to yield a highly significant positive effect on wound healing. Pain, a critical indicator of quality of life, was reported as being significantly reduced or eliminated within 72 hours after the ReCell treatment.
These data have been submitted as separate papers for publication in peer-reviewed journals.
“The early results achieved in the treatment of chronic ulcers with ReCell are highly promising,” CEO William Dolphin said in a statement, adding that these are hard-to-heal ulcers that pose an enormous burden on healthcare systems and seriously impact on patient’s quality of life.
ReCell is approved for use in Europe, Australia and other markets, with over 4,500 procedures conducted to date, mainly for burns. “Improved leg ulcer treatment will provide tremendous relief for ulcer patients, potentially deliver significant cost savings to financially stressed healthcare systems and may open additional very large markets for ReCell,” Dr. Dolphin said.
http://biotuesdays.com/2012/11/20/avita-initiates-european-recell-trial-in-lower-limb-ulcers/
I'll take a more steady lift rather than a quick spike.
Weight loss drug makers get a lift today after Aetna (AET -0.6%) revises its criteria under which the insurer considers weight reduction medications as "medically necessary" for treatment of obesity. In a Clinical Policy Bulletin revision dated yesterday, AET identified certain medications that have been approved by the FDA for weight reduction which would be covered under its policy: Qsymia, marketed by VIVUS (VVUS +13.2%), Belviq from Arena Pharmaceuticals (ARNA +2.9%), Didrex from Pfizer (PFE +0.1%), Xenical from Roche (RHHBY +0.3) and GlaxoSmithKline's (GSK +0.2%) Alli. Orexigen (OREX +6.5%), although not named in the bulletin, is also higher on the news
http://seekingalpha.com/currents/post/679211?source=email_rt_mc_readmore&ifp=0
http://www.quantumrareearth.com/press-releases/143-quantum-grants-options.html
"under its 2012 Stock Option Plan, for the purchase of up to 1,250,000 common shares of the Company for a period of 3 years at a price of $0.20 per share."
So Dickie has the right to buy options at .20 cents for a little over 2 more years but still chose to buy at .125. That's a good sign.
http://www.canadianinsider.com/node/7?menu_tickersearch=QRE+%7C+Quantum+Rare+Earth+Dvlpmt
there's the link, looks like half were warrants exercised. I'm working off a phone so I can't look up too much.
Prospectus: a document describing the major features of a proposed literary work, project, business venture, etc., in enough detail so that prospective investors, participants, or buyers may evaluate it.
I take it as something is in paper work stages but Dickie was still allowed to buy shares because of an exemption of some sort. Normally management can't buy a ton of shares right before something major happens. Definitely made my day.
That's great to hear! I would buy more because of that.
Response from Mickelson about Rice University.
I sent the professor a friendly email. I explained that I was a shareholder and this development from Rice was causing some stress for us. The question was if the SLM developed at Rice could be a threat to Lightwave. Looks like the answer is no...
"I know Qianfan Xu. He does good work. The point here, though, is that this advance does not address the problem being addressed by Lightwave. This silicon photon device of the article is simply a grating with electrodes. All silicon on insulator (SoI) photonic devices that my group has fabricated at IMEC during the last four years has been grating coupled. Grating couplers are standard on all ePIXfab devices and are common on all SoI devices wherever they are fabricated. What Xu has done is to dope the grates and then add electrodes. This is an advance but is an evolutionary one technically. One problem with the structure is that the electro optic (EO) effect of silicon is really small. This is the problem being addressed by Lightwave. Various groups, including mine in Colorado, have been addressing the problem of inserting nonlinear polymer into silicon photonics. Lightwave is addressing the problem of optimizing the material to be inserted on order that the EO coefficient is large enough to really have a significant effect on the incident light.
I hope my explanation helps to alleviate any anxiety. Have a great week,
Alan"
I'm going to hold off concerns until the very beginning of 2013. I was just having some fun with six shot. I believe that the merger is real. I was hoping to hear some other good news in November, it's only the 20th so perhaps we will.
Miracle On 111 Ruthar Drive.
Coming to an online brokerage account near you in December... Or maybe sometime in 2013, if not then definitely in 2014... maybe.
Melbourne - November 20, 2012; Prana Biotechnology today announced that the New York Academy of Science is hosting a symposium on November 29th titled "Targeting Metals in Alzheimer's and Other Neurodegenerative Diseases". Dr. Rudy Tanzi, the Joseph P. and Rose F. Kennedy Professor of Neurology at Harvard University and Prana's Chief Scientific Advisor, and Dr. Robert Cherny. Prana's Head of Research, will take part in the symposium. The presentations will explore the causative events leading to the neuropathology that drives Alzheimer's disease, Parkinson's disease and Huntington disease. This symposium will examine how these findings led to the discovery of small molecules designed to restore the balance of transition metals in the brain that are critical for neuronal function, reduce the accumulation of aggregated target proteins, and could have a disease-modifying effect. A review of Prana's PBT2 clinical history will be presented.
Dr. Tanzi said, "Researchers are increasingly focusing on the role of metals in neurodegenerative disease, providing data that promotes optimism for the outcome of Prana's trials. As we learn more about the genetics of Alzheimer's disease it appears that the disease is triggered by the excessive accumulation of the amyloid beta protein in the brain. Prana's therapeutic strategy for treating neurodegenerative disease involves a very different mechanism of action than that of other anti-beta-amyloid drugs, which have largely failed".
The symposium is presented by the Brain Dysfunction Discussion Group at the New York Academy of Sciences and is free for Academy members. Both members and non-members can register to attend the symposium or tune in via the live webinar at www.nyas.org/MetalsandAD (register free from Monday 26 Nov). Media should RSVP to Diana Friedman at dfriedman@nyas.org .
ASIC Granted Postponement of AGM until 12th December 2012
In accordance with Section 250P of the Corporation Act of 2001, Prana has been granted Australian Securities and Investment Commission (ASIC) approval to hold the 2012 Annual General Meeting on December 12, 2012 in order to enable Geoffrey Kempler, Chairman of Prana, to participate in the New York Academy of Science meeting on November 29th to discuss Prana and its scientific research.
About Prana Biotechnology Limited
Prana Biotechnology was established to commercialize research into age-related neurodegenerative disorders. The Company was incorporated in 1997 and listed on the Australian Securities Exchange in March 2000 and listed on NASDAQ in September 2002. Researchers at prominent international institutions including The University of Melbourne, The Mental Health Research Institute (Melbourne) and Massachusetts General Hospital, a teaching hospital of Harvard Medical School, contributed to the discovery of Prana's technology.
For further information please visit the Company's web site at www.pranabio.com.
Japanese End Users Scramble to Find Supply Outside China
This isn't an easy listen that's for sure. Quantum posted it on their twitter.
I have Ad Block on Google Chrome and it keeps the ads off my screen. I logged into Ihub on Internet Explorer and wow what a difference, ads everywhere. All my ads are for online brokerage accounts. That makes sense though, I recently rolled my work IRA over to a personal account and did alot of research before doing so.
It was probably 5 years ago when I first heard about cyber Monday and I thought it was kind of dumb. Why order something online and pay shipping when you can go to a store and buy it?
Now I think driving around with all the idiots on the road, waiting in check out lines, and sitting in traffic burning $4 a gallon gas is stupid when I can just order online.
Brick an mortar or online Vocus has something for you, so it's win win for shareholders.
Oh yea, what was I thinking.
Walter that sounds great! I found one typo, it's in the paragraph below, I made it red.
Last year some Chinese companies took a 15% stake in CBMM for about $2 billion as did a Japanese and Korean constortium for the same price tag and 15% ownership, making Niobium 3rd in M and A activity last year. CBMM provides I around 86% of the world’s demand. Having only one outlet that supplies almost everyone brings a certain amount of risk if your company has an absolute need for it. Something catastrophic or unexpected could happen at CBMM, then what do you do? In addition Tata, ArcelorMittal, Sumitomo, Mitsui, Severstal, Thyssenkrupp, Nucor, Evraz, Gruppo Riva, Hyundai, US Steel, Allegheny, IMIDRO, NMLK, NMK, China Steel (Taiwan), Steel Authority of India, Wisco and many others were all shut out of the CBMM deal and are need a long term supply. This will ring true by as early as 2018 when demand is predicted to potentially outstrip the maximum capacity of the three current producers.
Oxford, are you a Pran shareholder? You're 15 total posts on here have been for the most part negative. Well intentioned shareholders usually don't join to cast doubt.
Kada, it's great to have you and you're extensive knowledge of Prana on this board. BTW Surf is on literally every other biotech forum on Investors Hub as a moderator at this point.
Two thoughts. For a pre-revenue company that is trying to work out a possible merger they'll need every dollar they can get. It's expensive to pay the bankers, lawyers and accountants.
The extra 300k could also have been needed to satisfy a requirement this other company has about the amount of cash Lightwave has on hand.
"We recently began a second-generation design of a unique telecommunications modulator incorporating our newly developed material Perkinamine TM Indigo. We intend to have a working bench-top prototype in the near future. We will release a report when the bench-top prototype is completed and tested. We anticipate this modulator will be able to greatly exceed the performance of existing legacy modulators and will allow for improvements in the form of reduced power consumption and reduced device cost. The completion of the modulator using our Perkinamine Indigo TM materials is subject to the successful characterization of those materials both on a stand-alone basis and in a modulator design."
So from the sound of this they are close to having the required purity of Indigo needed for commercialization.
Does anyone know who Lightwave uses for legal services?
I shot myself in the foot with VOCS this time around. I was doing pretty well selling halfs on ups and downs since I got in back in February. I sold out totally that day in September it went up to 20.45. Then I bought back in the 18's thinking it would be easy money going into Q3 reporting. From watching the live trading it looked to me like the MM dropped the price 100 shares at a time, tripping stop losses, shaking out the weak hands along the way. I don't mind holding VOCS in the red. It will come back.
Yes, I forgot you don't post regularly, I should have been more clear. We have discussed Jody here before. In the past he purchased an endless amount of shares with his own money, along with receiving a salary from Quantum in shares. Last I knew he held around 5 million. So in reality a guy with that many shares unloading 100,000 isn't a big deal. He's doing it out of necessity, not a lack of belief in the company. But this stock being so thinly traded it gets knocked down easily when someone sells that many shares. I shouldn't complain since his sells have provided me excellent buying opportunities.
Upcoming catalyst. Q4 Vocus will be releasing their new integrated marketing suite. It will include email marketing, as well as new features and functionality.
Also, they had hired a few hundred new people before the end of the summer and plan to hire a few hundred more probably before the year is over. Many of them were sales staff. The normal ramp up time for a salesman there is 6-9 months. So you'll have the new hires from Q2/Q3 coming into their own this quarter and into Q1. Followed the by the others into Q2/Q3. I doubt Vocus loses money on the new sales staff, they just make less off of them. Either way at the rate they're going Vocus is poised for a strong 2013.
Hopefully you got back in before this week. The CEO bought 70,000 shares on 11/8/12. The MM really tanked the stock before that happened.
I'm happy to see it holding right around $4. Hopefully with our more clear future this will establish itself as a new base number.
I feel really confident after hearing that webcast. This is the reoccurring post of the day lol.
It was mostly from a wave a new buyers that were introduced to LWLG by WalterC nearly all at the same time.
Sixshot, that would finally get the stock price moving where it should be.
Just looked, Jody Darouge dragging us down again. This guy must be a financial mess. He is still the largest shareholder at the company I believe.
http://www.canadianinsider.com/node/7?menu_tickersearch=QRE+%7C+Quantum+Rare+Earth+Dvlpmt
Avita Presents at SoCalBio Conference. http://socalbio.org/SocalBio_2012/home_2012.htm
I just got off the phone with a Doctor from SoCalBio. I was calling to see when audio would be on the website. For whatever reason they don't record the conference. I'm disappointed that there is no audio of this but I won't let it detract from the positive mark for Avita. So big deal, Avita spoke at a conference? From what I'm reading this isn't A conference it's Thee conference. Southern California is the hub of bio-science companies, over 900 are in the region. Companies come from everywhere apply, but only 40 were selected to present.
The day after the conference some 12,000 shares of AVMXY were purchased. Perhaps a few opportunists were in the crowd?
If anyone is like me and always looking for compelling stocks, here is the list of companies that made it to the mic last week. A nice screener for good biotechs for sure. http://www.socalbio.org/SocalBio_2012/Presenters.htm
A Little Insider Buying!
https://www.otciq.com/otciq/ajax/showFinancialReportById.pdf?id=93781
It was an indirect purchase but I'll take that. As usual it did nothing for the share price because nobody is watching this stock. 150 shares traded today. I added 350 shares to my IRA a couple weeks ago. I still think the $8 price target is very realistic.
Copy and paste below.
Appendix 3Y
Change of Director’s Interest Notice
+ See chapter 19 for defined terms.
01/01/2011 Appendix 3Y Page 1
Rule 3.19A.2
Appendix 3Y
Change of Director’s Interest Notice
Information or documents not available now must be given to ASX as soon as available. Information and
documents given to ASX become ASX’s property and may be made public.
Introduced 30/09/01 Amended 01/01/11
Name of entity Avita Medical Limited
ABN 28 058 466 523
We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the
director for the purposes of section 205G of the Corporations Act.
Name of Director Ian Keith Macpherson
Date of last notice 22 October 2012
Part 1 - Change of director’s relevant interests in securities
In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust
Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should be
disclosed in this part.
Direct or indirect interest Indirect
Nature of indirect interest
(including registered holder)
Note: Provide details of the circumstances giving rise to the relevant
interest.
Shares held by Fats Pty Ltd and Macadam Pty
Ltd of which Mr Macpherson is a Director
and shareholder
Date of change 30 October 2012
No. of securities held prior to change Indirect 10,399,997 shares
Class Ordinary Fully Paid Shares
Number acquired 400,000
Number disposed -
Value/Consideration
Note: If consideration is non-cash, provide details and estimated
valuation
$0.12 per share
No. of securities held after change Indirect 10,799,997 Appendix 3Y
Change of Director’s Interest Notice
+ See chapter 19 for defined terms.
Appendix 3Y Page 2 01/01/2011
Nature of change
Example: on-market trade, off-market trade, exercise of options, issue of
securities under dividend reinvestment plan, participation in buy-back
Off-Market – Placement as approved by
shareholders at 19 October 2012 shareholder
meeting
Part 2 – Change of director’s interests in contracts
Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be
disclosed in this part.
Detail of contract
Nature of interest
Name of registered holder
(if issued securities)
Date of change
No. and class of securities to which
interest related prior to change
Note: Details are only required for a contract in relation
to which the interest has changed
Interest acquired
Interest disposed
Value/Consideration
Note: If consideration is non-cash, provide details and
an estimated valuation
Interest after change
Part 3 –
+Closed period
Were the interests in the securities or contracts detailed
above traded during a
+
closed period where prior written
clearance was required?
No
If so, was prior written clearance provided to allow the trade
to proceed during this period?
NA
If prior written clearance was provided, on what date was this
provided?
NA Appendix 3Y
Change of Director’s Interest Notice
+ See chapter 19 for defined terms.
30/9/2001 Appendix 3Y Page 1
Appendix 3Y
Change of Director’s Interest Notice
Information or documents not available now must be given to ASX as soon as available. Information and
documents given to ASX become ASX’s property and may be made public.
Introduced 30/9/2001.
Name of entity Avita Medical Limited
ABN 28 058 466 523
We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the
director for the purposes of section 205G of the Corporations Act.
Name of Director Dalton Leslie Gooding
Date of last notice 30 June 2011
Part 1 - Change of director’s relevant interests in securities
In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust
Direct or indirect interest Indirect
Nature of indirect interest
(including registered holder)
Note: Provide details of the circumstances giving rise to the
relevant interest.
Perth Investment Corporation – director &
beneficial shareholder
Moulyinning Nominees Pty Ltd – director &
beneficial shareholder
Date of change 30 October 2012
No. of securities held prior to change Indirect Perth Investment Corporation
2,014,288 shares
Indirect Moulyinning Nominees
1,048,573 shares
Class Ordinary Fully Paid Shares
Number acquired 291,667
Number disposed -
Value/Consideration
Note: If consideration is non-cash, provide details and estimated
valuation
$0.12 per share Appendix 3Y
Change of Director’s Interest Notice
+ See chapter 19 for defined terms.
Appendix 3Y Page 2 30/9/2001
No. of securities held after change Indirect Perth Investment Corporation
2,014,288 shares
Indirect Moulyinning Nominees
1,340,240 shares
Nature of change
Example: on-market trade, off-market trade, exercise of options,
issue of securities under dividend reinvestment plan,
participation in buy-back
Off-Market – Placement as approved by
shareholders at 19 October 2012 shareholder
meeting
Part 2 – Change of director’s interests in contracts
Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be
disclosed in this part.
Detail of contract
Nature of interest
Name of registered holder
(if issued securities)
Date of change
No. and class of securities to which
interest related prior to change
Note: Details are only required for a contract in relation
to which the interest has changed
Interest acquired
Interest disposed
Value/Consideration
Note: If consideration is non-cash, provide details and
an estimated valuation
Interest after change
Part 3 –
+Closed period
Were the interests in the securities or contracts detailed
above traded during a
+
closed period where prior written
clearance was required?
No
If so, was prior written clearance provided to allow the trade
to proceed during this period?
NA
If prior written clearance was provided, on what date was this
provided?
Yes via Shareholder notice of
meeting dated 17 May 2011 Appendix 3Y
Change of Director’s Interest Notice
+ See chapter 19 for defined terms.
30/9/2001 Appendix 3Y Page 1
Appendix 3Y
Change of Director’s Interest Notice
Information or documents not available now must be given to ASX as soon as available. Information and
documents given to ASX become ASX’s property and may be made public.
Introduced 30/9/2001.
Name of entity Avita Medical Limited
ABN 28 058 466 523
We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the
director for the purposes of section 205G of the Corporations Act.
Name of Director William Ford Dolphin
Date of last notice 5 October 2011
Part 1 - Change of director’s relevant interests in securities
In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust
Direct or indirect interest Direct
Nature of indirect interest
(including registered holder)
Note: Provide details of the circumstances giving rise to the
relevant interest.
William & Alison Dolphin <The
Dolphin Family Super Fund>
Date of change 30 October 2012
No. of securities held prior to change Indirect - William & Alison Dolphin <The
Dolphin Family Super Fund>
1,519,047 ordinary shares
Direct
359,522 ordinary shares
4,882,500 unlisted options, expiring
14/11/2014, exercise price $0.14
1,000,000 unlisted options, expiring
30/11/2015 exercise price $0.14
1,660,000 unlisted options, expiring
30/11/2016 exercise price $0.14
1,500,000 unlisted options, expiring
30/11/2017 exercise price $0.14
750,000 unlisted options, expiring
30/11/2018 exercise price $0.14
Class Ordinary Shares Appendix 3Y
Change of Director’s Interest Notice
+ See chapter 19 for defined terms.
Appendix 3Y Page 2 30/9/2001
Number acquired 125,000
Number disposed
Value/Consideration
Note: If consideration is non-cash, provide details and estimated
valuation
$0.12 per share
No. of securities held after change Indirect - William & Alison Dolphin <The
Dolphin Family Super Fund>
1,644,047 ordinary shares
Direct
359,522 ordinary shares
4,882,500 unlisted options, expiring
14/11/2014, exercise price $0.14
1,000,000 unlisted options, expiring
30/11/2015 exercise price $0.14
1,660,000 unlisted options, expiring
30/11/2016 exercise price $0.14
1,500,000 unlisted options, expiring
30/11/2017 exercise price $0.14
750,000 unlisted options, expiring
30/11/2018 exercise price $0.14
Nature of change
Example: on-market trade, off-market trade, exercise of options,
issue of securities under dividend reinvestment plan,
participation in buy-back
Off-Market – Placement as approved by
shareholders at 19 October 2012 shareholder
meeting
Part 2 – Change of director’s interests in contracts
Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be
disclosed in this part.
Detail of contract
Nature of interest
Name of registered holder
(if issued securities)
Date of change
No. and class of securities to which
interest related prior to change
Note: Details are only required for a contract in relation
to which the interest has changed
Interest acquired Appendix 3Y
Change of Director’s Interest Notice
+ See chapter 19 for defined terms.
30/9/2001 Appendix 3Y Page 3